Fresenius/€FRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Fresenius
- Ticker
- €FRE
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 178,486
- Headquarters
- Bad Homburg vor der Höhe, Germany
- Website
- www.fresenius.com
Fresenius Metrics
BasicAdvanced
€25B
16.51
€2.70
0.83
€1.05
2.35%
Price and volume
Market cap
€25B
Beta
0.83
52-week high
€47.33
52-week low
€42.10
Average daily volume
1.1M
Dividend rate
€1.05
Financial strength
Current ratio
1.28
Quick ratio
0.653
Long term debt to equity
0.468
Total debt to equity
0.56
Dividend payout ratio (TTM)
32.72%
Interest coverage (TTM)
5.42%
Profitability
EBITDA (TTM)
3,028.4
Gross margin (TTM)
25.35%
Net profit margin (TTM)
6.54%
Operating margin (TTM)
9.80%
Effective tax rate (TTM)
25.64%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
3.43%
Return on equity (TTM)
8.29%
Valuation
Price to earnings (TTM)
16.511
Price to revenue (TTM)
1.078
Price to book
1.28
Price to tangible book (TTM)
8.55
Price to free cash flow (TTM)
14.543
Free cash flow yield (TTM)
6.88%
Free cash flow per share (TTM)
3.068
Dividend yield (TTM)
2.35%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
3.38%
Earnings per share change (TTM)
35.46%
3-year revenue growth (CAGR)
2.59%
10-year revenue growth (CAGR)
-1.97%
3-year earnings per share growth (CAGR)
12.71%
10-year earnings per share growth (CAGR)
0.21%
3-year dividend per share growth (CAGR)
4.50%
10-year dividend per share growth (CAGR)
6.68%
Bulls say / Bears say
Fresenius delivered a strong Q2, with constant-currency EBIT up 10%, Core EPS up 14% and the 2026 Core EPS-growth target raised to 10–15% from 5–10%. (Reuters)
Kabi’s Growth Vectors are scaling rapidly: Q2 organic growth reached 12%, led by Biopharma at 38% and MedTech at 11%, while Growth Vectors EBIT increased 42% in constant currency. (Fresenius)
Helios is showing resilient operating momentum, with Q2 organic revenue growth of 5%, constant-currency EBIT growth of 10% and a margin increase to 10.6%, supported by activity, pricing and cost management in Germany and Spain. (Fresenius)
Fresenius Kabi’s Pharma business remains a drag: Q2 revenue grew only 1% organically, while EBIT fell 13% year over year, reflecting U.S. pricing pressure and manufacturing-adjustment costs. (Fresenius)
The upgraded 2026 outlook still carries meaningful execution risk because Fresenius flags heightened geopolitical, regulatory, tax, customs-duty and macroeconomic uncertainty. (Fresenius)
Some Q2 profit drivers may be difficult to repeat: Helios benefited from a German surcharge on invoices to publicly insured patients, while Kabi’s margin benefited from favorable mix, milestone receipts and phasing effects. (Fresenius)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Fresenius
AllEURGBPUSD
Fund name | Fund size | €FRE weighting |
|---|---|---|
iShares DivDAX€EXSB | €562M | 3.29% |
iShares Dax ESG€EXIA | €127M | 1.42% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 1.21% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 1.21% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 1.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.